The immuno-oncology field is seeing high-profile deals and increasing media attention.  We have therefore used the LSN company database to analyze a sample of biotech companies working in this field. Cancer immunotherapies harness the power of the immune system to target malignant cells. Unlike traditional approaches to cancer such as radiotherapy and chemotherapy, these emerging technologies hold the promise of precise therapeutic effects while leaving the rest of the body unharmed. These products' clinical benefits are impressive, and so is their financial performance. In 2014 alone, cancer immunotherapy drugs have generated about $41.0 billion in the United States, accounting for nearly 50% of the overall oncology drug market.

With more than 30,000 company profiles, LSN's company platform provides a bird's eye view of the global early stage biotech and medtech R&D landscape. Our search in the LSN company platform yielded 522 unique companies that are currently developing at least one cancer immunotherapy product. About one-fifth (119) of them are publicly listed, while the rest are private or subsidiary companies. Cancer immunotherapy R&D has become a global phenomenon with the United States the leader in terms of number of companies, followed by China, Germany, the United Kingdom, and Canada, as shown in Figure 1...

 READ MORE